Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 6/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893786 | 0.94 | MDM2 (0.51) | GABRA2GABRB2MDM2CHRNA7TRPM8 | |
| SCHEMBL9894878 | 0.89 | MDM2 (0.58) | GABRA2GABRB2MDM2TRPM8ALDH1A1 | |
| SCHEMBL9894113 | 0.87 | MDM2 (0.57) | GABRA2GABRB2MDM2CNR1CNR2 | |
| SCHEMBL1443291 | 0.85 | MDM2 (0.63) | GABRA2GABRB2MDM2CHRNA7TRPM8 | |
| SCHEMBL9894160 | 0.85 | GABRA2 (0.46) | GABRA2GABRB2MDM2CHRNA7TRPM8 | |
| SCHEMBL9893850 | 0.84 | PDE4B (0.45) | MDM2CNR1CNR2 | |
| SCHEMBL9893774 | 0.80 | KDM4E (0.47) | GABRA2GABRB2CHRNA7MAPK1ALDH1A1 | |
| SCHEMBL9893913 | 0.80 | MDM2 (0.51) | GABRA2GABRB2MDM2CHRNA7TRPM8 | |
| SCHEMBL1437218 | 0.80 | ALDH1A1 (0.48) | GABRA2GABRB2TRPM8ALDH1A1KMT2A | |
| SCHEMBL9893814 | 0.79 | MDM2 (0.64) | GABRA2GABRB2MDM2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | GABRA2 4293/4885GABRB2 4278/4885MDM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.